127 related articles for article (PubMed ID: 1631501)
1. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer.
Røhl HF; Beuke HP
Scand J Urol Nephrol; 1992; 26(1):11-4. PubMed ID: 1631501
[TBL] [Abstract][Full Text] [Related]
2. Hormonal consequences of orchidectomy for carcinoma of the prostate. With special reference to the measurement of free testosterone in saliva and prostatic dihydrotestosterone levels.
Boccon-Gibod L; Laudat MH; Guiban D; Steg A
Eur Urol; 1988; 15(1-2):99-102. PubMed ID: 3215246
[TBL] [Abstract][Full Text] [Related]
3. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
4. Subcapsular orchidectomy in the management of prostatic carcinoma in Nigerians.
Magoha GA
East Afr Med J; 1989 Jun; 66(6):400-3. PubMed ID: 2791945
[TBL] [Abstract][Full Text] [Related]
5. Effect of orchidectomy performed after cessation of estrogen therapy on serum testosterone concentrations in patients with prostatic carcinoma.
Tomić R; Damber JE
Urol Int; 1987; 42(6):441-4. PubMed ID: 3129850
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
Lukkarinen O; Hammond GL; Kontturi M; Vihko R
Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
[TBL] [Abstract][Full Text] [Related]
7. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
8. Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer.
Van Poppel H; Werbrouck PW; Baert L
Acta Urol Belg; 1990; 58(4):89-95. PubMed ID: 2093302
[TBL] [Abstract][Full Text] [Related]
9. [Interdependence between hormonal disorders, stage of development and degree of malignancy of prostatic cancer. 1].
Szymanowski J; Baranowska B; Niewiadomska A; Wysocki M; Kobuszewska-Faryna M; Zgliczynski S
J Urol (Paris); 1983; 89(8):597-600. PubMed ID: 6677708
[TBL] [Abstract][Full Text] [Related]
10. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
[TBL] [Abstract][Full Text] [Related]
11. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
12. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
13. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
14. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
Wenderoth UK; Jacobi GH
Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
[TBL] [Abstract][Full Text] [Related]
15. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
16. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
17. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
18. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
[TBL] [Abstract][Full Text] [Related]
19. Is pre-treatment testosterone a prognostic factor in prostate cancer?
Akumabor PN
Cent Afr J Med; 1993 Aug; 39(8):170-2. PubMed ID: 8020082
[TBL] [Abstract][Full Text] [Related]
20. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
